2022
Cost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke
Zhou LW, Kraler L, de Havenon A, Lansberg MG. Cost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke. Journal Of The American Heart Association 2022, 11: e024992. PMID: 35656996, PMCID: PMC9238703, DOI: 10.1161/jaha.121.024992.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsHealth care costsHigher quality-adjusted life yearsNet monetary benefitLifetime quality-adjusted life yearsProbabilistic sensitivity analysesCare costsMonetary benefitsSensitivity analysisLife yearsCost inputsLifetime costsLower health care costsCost savingsCostBest available dataWillingnessSavingsMonte Carlo simulationsTreatment effectsCarlo simulationsAvailable dataBenefitsDecision tree
2019
Results From DEFUSE 3
de Havenon A, Mlynash M, Kim-Tenser MA, Lansberg MG, Leslie-Mazwi T, Christensen S, McTaggart RA, Alexander M, Albers G, Broderick J, Marks MP, Heit JJ, Investigators O. Results From DEFUSE 3. Stroke 2019, 50: 632-638. PMID: 30726184, PMCID: PMC6628906, DOI: 10.1161/strokeaha.118.023407.Peer-Reviewed Original ResearchConceptsIschemic core volumeLarge vessel occlusionEndovascular thrombectomyCollateral statusTomography angiographyFunctional independenceDEFUSE 3Poor collateralsLeptomeningeal collateralsStroke patientsVessel occlusionGood collateralsAnterior circulation large vessel occlusionBaseline ischemic core volumeSmall ischemic core volumeAcute ischemic stroke patientsDEFUSE 3 patientsIschemic stroke patientsModified Rankin ScaleStroke-related deathComputed tomography angiographyGood leptomeningeal collateralsTreatment effectsNeurological outcomePrespecified analysis